Surpass flow diverter in the treatment of intracranial aneurysms: a prospective multicenter study
| Autor: | Wakhloo, A.K., Lylyk, P., De Vries, J., Taschner, C., Lundquist, J., Biondi, A., Hartmann, M., Szikora, I., Pierot, L., Sakai, N., Imamura, H., Sourour, N., Rennie, I., Skalej, M., Beuing, O., Bonafé, A., Mery, F., Turjman, F., Brouwer, P., Boccardi, E., Valvassori, L., Derakhshani, S., Litzenberg, M.W., Gounis, M.J., Study Group, Surpass |
|---|---|
| Přispěvatelé: | Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Neuroradiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département de Neuroradiologie[Montpellier], Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL), Radiology & Nuclear Medicine |
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging medicine.medical_treatment [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Aneurysm Blood vessel prosthesis Occlusion medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Embolization cardiovascular diseases Prospective cohort study Intraparenchymal hemorrhage Stroke Aged Aged 80 and over Interventional medicine.diagnostic_test business.industry Other Research Radboud Institute for Health Sciences [Radboudumc 0] Intracranial Aneurysm Middle Aged medicine.disease Embolization Therapeutic Blood Vessel Prosthesis Cerebral Angiography 3. Good health Surgery Treatment Outcome Angiography Female [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] Neurology (clinical) business [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | AJNR American Journal of Neuroradiology, 36, 1, pp. 98-107 American Journal of Neuroradiology American Journal of Neuroradiology, American Society of Neuroradiology, 2015, 36 (1), pp.98-107. ⟨10.3174/ajnr.A4078⟩ AJNR American Journal of Neuroradiology, 36, 98-107 American Journal of Neuroradiology, 36(1), 98-107. American Society of Neuroradiology AJNR Am J Neuroradiol |
| ISSN: | 0195-6108 |
| DOI: | 10.3174/ajnr.A4078⟩ |
| Popis: | Item does not contain fulltext BACKGROUND AND PURPOSE: Incomplete occlusion and recanalization of large and wide-neck brain aneurysms treated by endovascular therapy remains a challenge. We present preliminary clinical and angiographic results of an experimentally optimized Surpass flow diverter for treatment of intracranial aneurysms in a prospective, multicenter, nonrandomized, single-arm study. MATERIALS AND METHODS: At 24 centers, 165 patients with 190 intracranial aneurysms of the anterior and posterior circulations were enrolled. The primary efficacy end point was the percentage of intracranial aneurysms with 100% occlusion on 6-month DSA. The primary safety end point was neurologic death and any stroke through a minimum follow-up of 6 months. RESULTS: Successful flow-diverter delivery was achieved in 161 patients with 186 aneurysms (98%); the mean number of devices used per aneurysm was 1.05. Clinical follow-up (median, 6 months) of 150 patients (93.2%), showed that the primary safety end point occurred in 18 subjects. Permanent neurologic morbidity and mortality were 6% and 2.7%, respectively. Morbidity occurred in 4% and 7.4% of patients treated for aneurysms of the anterior and posterior circulation, respectively. Neurologic death during follow-up was observed in 1.6% and 7.4% of patients with treated intracranial aneurysms of the anterior and posterior circulation, respectively. Ischemic stroke at 30 days or SAH at >7 days occurred. New or worsening cranial nerve deficit was observed in 2.7%. Follow-up angiography available in 158 (86.8%) intracranial aneurysms showed 100% occlusion in 75%. CONCLUSIONS: Clinical outcomes of the Surpass flow diverter in the treatment of intracranial aneurysms show a safety profile that is comparable with that of stent-assisted coil embolization. Angiographic results showed a high rate of intracranial aneurysm occlusion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|